Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleGout

Analysis of Gout Remission Definitions in a Randomized Controlled Trial of Colchicine Prophylaxis for People With Gout Initiating Allopurinol

Adwoa Dansoa Tabi-Amponsah, Lisa K. Stamp, Anne Horne, Jill Drake, Sarah Stewart, Greg Gamble, Keith J. Petrie and Nicola Dalbeth
The Journal of Rheumatology November 2024, 51 (11) 1135-1140; DOI: https://doi.org/10.3899/jrheum.2024-0400
Adwoa Dansoa Tabi-Amponsah
1A.D. Tabi-Amponsah, BBiomedSc(Hons), A. Horne, MBChB, G. Gamble, MSc, N. Dalbeth, MD, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adwoa Dansoa Tabi-Amponsah
Lisa K. Stamp
2L.K. Stamp, PhD, Department of Medicine, University of Otago, Christchurch, Christchurch;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lisa K. Stamp
Anne Horne
1A.D. Tabi-Amponsah, BBiomedSc(Hons), A. Horne, MBChB, G. Gamble, MSc, N. Dalbeth, MD, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne Horne
Jill Drake
3J. Drake, RN, Department of Rheumatology, Immunology and Allergy, Te Whatu Ora Health New Zealand Waitaha Canterbury, Christchurch;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Stewart
4S. Stewart, PhD, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, and School of Clinical Sciences, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah Stewart
Greg Gamble
1A.D. Tabi-Amponsah, BBiomedSc(Hons), A. Horne, MBChB, G. Gamble, MSc, N. Dalbeth, MD, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Greg Gamble
Keith J. Petrie
5K.J. Petrie, PhD, Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Keith J. Petrie
Nicola Dalbeth
1A.D. Tabi-Amponsah, BBiomedSc(Hons), A. Horne, MBChB, G. Gamble, MSc, N. Dalbeth, MD, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicola Dalbeth
  • For correspondence: n.dalbeth{at}auckland.ac.nz
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fulfillment of individual domains by intervention over the (A) first 6 months and (B) last 6 months. PtGA: patient global assessment.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Fulfillment of individual domains by intervention over the (A) first 6 months and (B) last 6 months. PtGA: patient global assessment.

  • Fulfillment of remission definitions over 6-monthly periods.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Fulfillment of remission definitions over 6-monthly periods.

Tables

  • Figures
  • Additional Files
    • View popup
    Table 1.

    Six-monthly fulfillment of the 2016 preliminary gout remission definition and the simplified gout remission definition according to randomized group.

    Six-monthly Fulfillment of the 2016 Preliminary Definition
    Colchicine,
    n = 100
    Placebo,
    n = 100
    OR (95% CI)aP
    Months 1-63 (3)4 (4)0.62 (0.12-3.18)0.57
    Months 7-124 (4)14 (14)0.29 (0.09-0.90)0.03
    Six-monthly Fulfillment of the Simplified Definition
    Colchicine,
    n = 100
    Placebo,
    n = 100
    OR (95% CI)aP
    Months 1-67 (7)12 (12)0.61 (0.22-1.68)0.34
    Months 7-1214 (14)28 (28)0.41 (0.20-0.85)0.02
    • ↵a Participants in placebo group were used as the reference. OR: odds ratio.

    • View popup
    Table 2.

    Comparison of month 12 BIPQ scores between those who fulfilled and did not fulfill the 2016 preliminary gout remission definition in the final 6 months of the trial (months 7-12).

    Belief TypeBIPQ ItemaFulfilled,
    n = 18,
    mean (95% CI)
    Not Fulfilled,
    n = 182,
    mean (95% CI)
    Mean Difference
    (95% CI)
    P
    ConsequenceHow much does gout affect your life?
    (10 = severely affects life)
    0.86 (−0.53 to 2.26)2.18 (1.75 to 2.63)1.32 (−0.10 to 2.75)0.07
    TimelineHow long do you think your gout will continue?
    (10 = will continue forever)
    8.78 (6.84 to 10.73)7.58 (6.99 to 8.16)−1.20 (−3.22 to 0.80)0.25
    Personal controlHow much control do you feel you have over your
    gout? (10 = extreme amount)
    9.02 (7.86 to 10.19)8.12 (7.70 to 8.54)−0.90 (−2.12 to 0.32)0.15
    Treatment
    control
    How much do you think your treatment can
    help your gout? (10 = extremely helpful)
    8.96 (7.95 to 9.98)8.81 (8.42 to 9.21)−0.15 (−1.21 to 0.91)0.77
    IdentityHow much do you experience symptoms from
    your gout? (10 = many severe symptoms)
    0.89 (−0.21 to 2.00)2.10 (1.72 to 2.50)1.21 (0.05 to 2.37)0.04
    ConcernHow concerned are you about your gout?
    (10 = extremely concerned)
    1.20 (−0.34 to 2.73)3.40 (2.84 to 3.96)2.20 (0.63 to 3.77)0.01
    UnderstandingHow well do you feel you understand your gout?
    (10 = very clearly)
    8.70 (7.71 to 9.69)8.35 (8.00 to 8.71)−0.35 (−1.38 to 0.67)0.48
    Emotional
    response
    How much does your gout affect you emotionally?
    (10 = extremely affected)
    0.97 (−0.39 to 2.33)2.10 (1.65 to 2.55)1.13 (−0.22 to 2.48)0.08
    • ↵a Each question was rated on a 0-10 Likert scale. BIPQ: Brief Illness Perception Questionnaire.

    • View popup
    Table 3.

    Comparison of month 12 BIPQ scores between those who fulfilled and did not fulfill the simplified gout remission definition in the final 6 months of the trial (months 7-12).

    Belief TypeBIPQ ItemaFulfilled,
    n = 42,
    mean (95% CI)
    Not Fulfilled,
    n = 158,
    mean (95% CI)
    Mean Difference
    (95% CI)
    P
    ConsequenceHow much does gout affect your life?
    (10 = severely affects life)
    0.84 (−0.01 to 1.70)2.39 (1.91 to 2.87)1.55 (0.61 to 2.48)0.002
    TimelineHow long do you think your gout will
    continue? (10 = will continue forever)
    8.03 (6.94 to 9.14)7.49 (6.84 to 8.15)−0.54 (−1.77 to 0.68)0.39
    Personal controlHow much control do you feel you have
    over your gout? (10 = extreme amount)
    8.71 (7.94 to 9.48)8.07 (7.60 to 8.53)−0.64 (−1.50 to 0.22)0.15
    Treatment controlHow much do you think your treatment
    can help your gout? (10 = extremely helpful)
    9.07 (8.38 to 9.75)8.77 (8.33 to 9.20)−0.30 (−1.04 to 0.44)0.44
    IdentityHow much do you experience symptoms
    from your gout? (10 = many severe symptoms)
    0.80 (−0.01 to 1.62)2.29 (1.86 to 2.71)1.49 (0.60 to 2.37)0.002
    ConcernHow concerned are you about your gout?
    (10 = extremely concerned)
    1.61 (0.53 to 2.69)3.59 (2.97 to 4.20)1.98 (0.83 to 3.12)0.002
    UnderstandingHow well do you feel you understand your
    gout? (10 = very clearly)
    8.65 (7.97 to 9.33)8.35 (7.96 to 8.74)−0.30 (−1.04 to 0.45)0.43
    Emotional responseHow much does your gout affect you
    emotionally? (10 = extremely affected)
    1.29 (0.42 to 2.16)2.19 (1.70 to 2.69)0.90 (−0.06 to 1.86)0.07
    • ↵a Each question was rated on a 0-10 Likert scale. BIPQ: Brief Illness Perception Questionnaire.

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • 2024-0400DataSuppl.pdf
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 51, Issue 11
1 Nov 2024
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Analysis of Gout Remission Definitions in a Randomized Controlled Trial of Colchicine Prophylaxis for People With Gout Initiating Allopurinol
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Analysis of Gout Remission Definitions in a Randomized Controlled Trial of Colchicine Prophylaxis for People With Gout Initiating Allopurinol
Adwoa Dansoa Tabi-Amponsah, Lisa K. Stamp, Anne Horne, Jill Drake, Sarah Stewart, Greg Gamble, Keith J. Petrie, Nicola Dalbeth
The Journal of Rheumatology Nov 2024, 51 (11) 1135-1140; DOI: 10.3899/jrheum.2024-0400

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Analysis of Gout Remission Definitions in a Randomized Controlled Trial of Colchicine Prophylaxis for People With Gout Initiating Allopurinol
Adwoa Dansoa Tabi-Amponsah, Lisa K. Stamp, Anne Horne, Jill Drake, Sarah Stewart, Greg Gamble, Keith J. Petrie, Nicola Dalbeth
The Journal of Rheumatology Nov 2024, 51 (11) 1135-1140; DOI: 10.3899/jrheum.2024-0400
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
    • ONLINE SUPPLEMENT
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Keywords

COLCHICINE
GOUT
REMISSION

Related Articles

Cited By...

More in this TOC Section

  • Effectivity and Safety of Febuxostat in Reducing Serum Urate in Gout Patients With Chronic Kidney Disease: A Prospective Multicenter ULTRA Registry Study
  • Do Monosodium Urate Crystals Reduce at Different Rates in Joints and Tendons During Urate-Lowering Therapy? A Dual-Energy Computed Tomography Study
  • Inpatient Management of Gout: Serum Urate Testing and Allopurinol Dose Adjustment
Show more Gout

Similar Articles

Keywords

  • colchicine
  • gout
  • remission

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire